RxDoctor Payments Data

Stanley Kim, MD

Ophthalmology · Los Angeles, CANPI 1003837840

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 45 payments — averaging $31.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$441
  • Ivantis, Inc$184
  • Medtronic$142
  • AbbVie$138
  • Oyster Point Pharma, Inc.$115
  • Amgen$103
  • plus $296 from 10 others

What the payments were for

  • Food & beverage$1,38297%
  • Gifts$373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,419 in reported general payments places this provider in the 50th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$155,507
Medicare patients
441
Services billed
1,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine800$560,273
Cyclosporine281$105,011
LumiganBimatoprost215$67,413
RocklatanNetarsudil Mesylat/Latanoprost52$24,535
SimbrinzaBrinzolamide/Brimonidine Tart85$20,456
CombiganBrimonidine Tartrate/Timolol59$14,623
VyzultaLatanoprostene Bunod35$11,310
Brimonidine Tartrate107$9,900
XiidraLifitegrast14$9,823
Alphagan PBrimonidine Tartrate33$8,280
Latanoprost867$5,387
MoxifloxacinMoxifloxacin Hcl210$4,855
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol39$4,582
RhopressaNetarsudil Mesylate14$4,367
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat314$4,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$138$650,5891,107 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$41$21,13349 claims
AlconSimbrinza$49$20,45685 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →